Huakang Biomedical Holdings Company Limited

SEHK:8622 Stock Report

Market Cap: HK$91.1m

Huakang Biomedical Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chunguang Zhang

Chief executive officer

CN¥703.0k

Total compensation

CEO salary percentage44.7%
CEO tenure7.3yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure4.3yrs

Recent management updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11
Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11
Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

CEO Compensation Analysis

How has Chunguang Zhang's remuneration changed compared to Huakang Biomedical Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥6m

Mar 31 2024n/an/a

-CN¥6m

Dec 31 2023CN¥703kCN¥314k

-CN¥6m

Sep 30 2023n/an/a

-CN¥5m

Jun 30 2023n/an/a

-CN¥4m

Mar 31 2023n/an/a

-CN¥3m

Dec 31 2022CN¥689kCN¥308k

-CN¥3m

Sep 30 2022n/an/a

-CN¥2m

Jun 30 2022n/an/a

-CN¥3m

Mar 31 2022n/an/a

-CN¥4m

Dec 31 2021CN¥399kCN¥271k

-CN¥4m

Sep 30 2021n/an/a

-CN¥7m

Jun 30 2021n/an/a

-CN¥8m

Mar 31 2021n/an/a

-CN¥10m

Dec 31 2020CN¥727kCN¥250k

-CN¥12m

Sep 30 2020n/an/a

-CN¥9m

Jun 30 2020n/an/a

-CN¥7m

Mar 31 2020n/an/a

-CN¥3m

Dec 31 2019CN¥349kCN¥227k

-CN¥284k

Sep 30 2019n/an/a

-CN¥3m

Jun 30 2019n/an/a

-CN¥2m

Mar 31 2019n/an/a

-CN¥377k

Dec 31 2018CN¥284kCN¥234k

-CN¥459k

Dec 31 2017CN¥243kCN¥183k

-CN¥2m

Compensation vs Market: Chunguang's total compensation ($USD96.35K) is below average for companies of similar size in the Hong Kong market ($USD231.13K).

Compensation vs Earnings: Chunguang's compensation has increased whilst the company is unprofitable.

CEO

Chunguang Zhang (56 yo)

7.3yrs

Tenure

CN¥703,000

Compensation

Mr. Chunguang Zhang is Chief Executive officer at Huakang Biomedical Holdings Company Limited. Mr. Zhang is mainly responsible for business operations and the day-to-day management of Group. Mr. Zhang has...

Board Members

NamePositionTenureCompensationOwnership
Shuguang Zhang
Chairman of the Board7.3yrsCN¥479.00k27.71%
HK$ 25.2m
Chunguang Zhang
CEO & Executive Director7.3yrsCN¥703.00kno data
Lai Yin Poon
CFO, Compliance Officer & Executive Director7.3yrsCN¥769.00k0.80%
HK$ 728.0k
Jiaming He
Business Development Director & Executive Director4.9yrsCN¥484.00kno data
Faat Ting Cheng
Independent Non Executive Director4.3yrsCN¥90.00kno data
Yim Yang Chang
Vice Chairman of King Grace Company Limitedno datano datano data
Ming Xu
Non-Executive Directorless than a yearno datano data
Kwok Fai Chow
Independent Non-Executive Director4yrsCN¥90.00kno data
Ching Man Chow
Independent Non-Executive Director1.3yrsCN¥38.00kno data
Mei Ling Shih
Independent Non-Executive Directorno datano datano data

4.3yrs

Average Tenure

53yo

Average Age

Experienced Board: 8622's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 18:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Huakang Biomedical Holdings Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution